Today we celebrate👉
#FHAwarenessDay‼️, during which we should talk about the
#disease, necessity of its early
#diagnosis, suitable effective
#management and how to prevent
#ASCVD #complications.
I would like to share with you our recent data from the PMMHRI-FH Registry (NCT06571630) we presented during the
#ESCCongress2024 in London, which shows the real-life challenges with the suitable FH diagnosis and management.
Take home messages:
👉 we still diagnose very late, adults at median age of 44 years and children at the age of 9;
👉triple
#combination #LLT was used in only 28% of patients, what is a critical call for action to extend the criteria for the
#B101 #drugprogram with
#PCSK9 modulators in Poland (all FH patients should be eligible to be treated with these drugs);
👉 despite optimal combination LLT, only 62%‼️adult patients were on the LDL-C target (71% of children);
👉 despite being effectively treated with triple LLT, 5% of patients experienced
#MI, what put an attention for necessity to look at all
#residual #CVD #riskfactors in FH
#patients;
👉triple combination LLT was associated with the
#LDLC reduction by 74.42% (by mean absolute reduction of 190 mg/dL) and increased the chance to achieve LDL-C
#goal almost 5 times!
👉PCSK9 inhibitors were also associated with significant 45% reduction of
#LPA in FH patients.
The all results will be available soon, the presented data you can find here:
esc365.escardio.org/presenta…